Hello
Answers received
PAD: minimal biopsy from right kidney, image consistent with clear cell carcinoma. Malignancy grade 1.
Assessment
The patient is informed of the PAD response by telephone.
Regarding the patient's prostate cancer, stop Bicalutamide since May 2022. The patient has checked the PSA value privately. PSA was 0.45 in June, 0.95 in July and rose further to 1.1 when sampled on August 11. The patient has started taking the Bicalutamide tablets again since a week ago.
Measure
Planned actions
Return visit to the urology clinic with Dr. Ellasy or Alamdari for discussion regarding further management of the kidney tumor. New PSA check in four weeks with subsequent phone call with signed for prostate cancer follow-up.
Booking documents already created.
Diagnostic and Action Code
C619-Malignant tumor of the prostate-Main diagnosis
C649-Malignant tumor of kidney with the exception of the renal pelvis